Two years ago this month, Morphic made a rare foray into the "battleground" that is Australian property views. We say battleground because, a bit like schooling, everyone has an opinion as everyone has an experience and that opinion is...

Through 2018, many of our investors may well have become bored listening to our endless repetitions of the warning that a market correction was "just around the corner". In October, the correction arrived in all major markets: the US...

We are proud to present our second annual form guide for the 'LIC Cup'. This race is even bigger than the Melbourne Cup! There is approximately $35 billion of gamblers' (investors') money at stake in this sector, so the stakes are...

October's share market plunge confirms the view that traditional investment methodologies have their limitations and can be a very unsettling way to protect and grow your wealth, according to Jon Horton of NWQ Capital Management, who...

Investors will remember that we have been nagging them about the coming correction. Now that it's here, the big question is how bad will it be.

Unless you've been living under a rock these past few years, you've undoubtedly been barraged by news of the 'latest and greatest' iterations of blockchain technology. Whether it be Bitcoin, Ethereum or any of the seemingly endless supply...

The old saying about averages that "when your head is in the freezer and your feet are in the oven, overall your temperature is average" is particularly relevant when looking at the investment returns of managed funds, when "average" can...

Generally speaking, managed funds are required to have a minimum track record of 3 years, preferably 5, before being able to achieve a recommended rating and thus make it onto the prized Approved Product Lists or APL's of platforms and...

As of today, the All Ords will have pulled back more than 10% in less than two months. It's officially a correction now. Here are four strategies on how to cope.

The Fund Manager of the Pengana Absolute Return Asia Pacific Fund discusses the M&A deal between Takeda Pharmaceutical and Shire Pharmaceutical.